Blonanserin

Blonanserin (CAS 132810-10-7), also referenced under development codes AD-5423 and DSP-5423, is an atypical antipsychotic compound developed for the treatment of schizophrenia.

It functions as a dopamine D2/D3 and serotonin 5-HT2A receptor antagonist, positioning it as a key active pharmaceutical ingredient in CNS-targeted drug development pipelines.

Blonanserin is primarily sourced as an API or pharmaceutical intermediate for the manufacture of antipsychotic drug products, including tablets and transdermal patch formulations.

Contract manufacturers and generic drug developers use it as a reference standard or synthesis starting material when developing CNS formulations targeting schizophrenia.

Research organizations and CROs procure this material for receptor binding studies and comparative pharmacological profiling in psychiatric drug discovery programs.

It is also evaluated as an intermediate in the synthesis of structurally related heterocyclic compounds within medicinal chemistry workflows for new drug development.

Blonanserin is available as a white to off-white crystalline powder in research, pilot, and commercial quantities. Supply is offered under pharmaceutical-grade specifications.

High-purity material, typically ≥98% by HPLC, is suitable for API manufacturing and analytical reference use. Packaging ranges from milligram-scale to kilogram lots.